The study of the effect of thiazoline ammonium 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate on blood coagulation upon intragastric and subcutaneous administration.

We studied the effects of subcutaneous and intragastrical administration of synthesized compound thiazoline ammonium 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate (FS 169) on blood clotting in vitro and in vivo in rabbits. Compound FS 169 significantly prolongs clotting time in vitro; its activity is comparable with that of heparin. When administered subcutaneously, the substance is rapidly absorbed and significantly reduces blood clotting by 102.9% from the initial clotting time within 30 min. After intragastric administration of the substance, maximum activity (133.0% of the baseline clotting time) was observed in 30 min after administration. The drug effect upon subcutaneous and intragastrical administration lasted for 2 h.

[Comparative study of the effects of 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate and heparin on blood coagulation].

The purpose of this work investigation to study the effect of 4-chlorophenyl-2-hydroxy-4-oxo-2-butenoate (thiazoline ammonium butenoate, compound FS 169) and heparin on the coagulation of whole rabbit blood in vitro and in vivo. The effects of heparin and FS 169 were investigated using a Minilab 701 coagulometer. Citrated (3.8%) blood of outbred rabbits was used in a volumetric ratio of 9 : 1. In the experiments in vivo, heparin and FS 169 were introduced subcutaneously. The results showed that FS 169 in vitro reduced the blood clotting time 3.8 times; in vivo, this compound in a dose of 1/40 LD50 decreased the clotting time 2 times within 30 min after introduction. The drug effect upon subcutaneous administration lasted for 2 h. The activity of FS 169 both in vitro and in vivo was comparable with the activity of heparin.